Submitted by Anonymous (not verified) on 18 April 2024 - 8:36
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 17, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 17, Status: Authorised